NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
23.65
+0.95 (4.19%)
At close: Mar 28, 2024, 4:00 PM
24.12
+0.47 (1.99%)
After-hours: Mar 28, 2024, 7:46 PM EDT

NAMS Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Year 2023202220212020
Revenue
14.09102.6900
Revenue Growth (YoY)
-86.28%---
Gross Profit
14.09102.6900
Selling, General & Admin
37.6319.5161.38
Research & Development
159.4286.7428.974.05
Operating Expenses
197.06106.2534.985.43
Operating Income
-182.97-3.56-34.98-5.43
Interest Expense / Income
00.290.410.34
Other Expense / Income
-6.0618.796.4-0.02
Pretax Income
-176.91-22.63-41.79-5.75
Income Tax
0.03000
Net Income
-176.94-22.63-41.79-5.75
Shares Outstanding (Basic)
9778187
Shares Outstanding (Diluted)
--187
Shares Change
25.32%337.60%155.70%-
EPS (Basic)
-2.15-1.19-3.81-0.54
EPS (Diluted)
-2.15-1.19-3.81-0.54
Free Cash Flow
-141.2410.44-29.54-5.98
Free Cash Flow Per Share
-1.450.13-1.66-0.91
Gross Margin
100.00%100.00%--
Operating Margin
-1298.56%-3.46%--
Profit Margin
-1255.76%-22.04%--
Free Cash Flow Margin
-1002.43%10.17%--
EBITDA
-176.86-22.34-41.37-5.4
EBITDA Margin
-1255.22%-21.75%--
Depreciation & Amortization
0.050.010.010
EBIT
-176.91-22.35-41.37-5.41
EBIT Margin
-1255.57%-21.76%--
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).